My NCBI | Sign In
RSS Settings
  • Search:

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

    Results: 1 to 20 of 722

    1.

    Cost-effectiveness of full medicare coverage of angiotensin-converting enzyme inhibitors for beneficiaries with diabetes.

    Rosen AB, Hamel MB, Weinstein MC, Cutler DM, Fendrick AM, Vijan S.

    Ann Intern Med. 2005 Jul 19;143(2):89-99.PMID: 16027450 [PubMed - indexed for MEDLINE]Related articlesFree article

    2.

    Summaries for patients. The cost-effectiveness of full Medicare coverage of angiotensin-converting enzyme inhibitors for patients with diabetes.

    [No authors listed]

    Ann Intern Med. 2005 Jul 19;143(2):I21. No abstract available. PMID: 16027445 [PubMed - indexed for MEDLINE]Related articlesFree article

    3.

    The cost-effectiveness of treating all patients with type 2 diabetes with angiotensin-converting enzyme inhibitors.

    Golan L, Birkmeyer JD, Welch HG.

    Ann Intern Med. 1999 Nov 2;131(9):660-7.PMID: 10577328 [PubMed - indexed for MEDLINE]Related articlesFree article

    4.

    Cost-effectiveness of providing full drug coverage to increase medication adherence in post-myocardial infarction Medicare beneficiaries.

    Choudhry NK, Patrick AR, Antman EM, Avorn J, Shrank WH.

    Circulation. 2008 Mar 11;117(10):1261-8. Epub 2008 Feb 19.PMID: 18285564 [PubMed - indexed for MEDLINE]Related articlesFree article

    5.

    Cost-effectiveness of intensive glycemic control, intensified hypertension control, and serum cholesterol level reduction for type 2 diabetes.

    CDC Diabetes Cost-effectiveness Group.

    JAMA. 2002 May 15;287(19):2542-51.PMID: 12020335 [PubMed - indexed for MEDLINE]Related articlesFree article

    6.

    Cost effectiveness of ACE inhibitor treatment for patients with type 1 diabetes mellitus.

    Dong FB, Sorensen SW, Manninen DL, Thompson TJ, Narayan V, Orians CE, Gregg EW, Eastman RC, Dasbach EJ, Herman WH, Newman JM, Narva AS, Ballard DJ, Engelgau MM.

    Pharmacoeconomics. 2004;22(15):1015-27.PMID: 15449965 [PubMed - indexed for MEDLINE]Related articles

    7.

    To pay or not to pay? A decision and cost-utility analysis of angiotensin-converting-enzyme inhibitor therapy for diabetic nephropathy.

    Clark WF, Churchill DN, Forwell L, Macdonald G, Foster S.

    CMAJ. 2000 Jan 25;162(2):195-8. Erratum in: CMAJ 2000 Apr 4;162(7):973. PMID: 10674051 [PubMed - indexed for MEDLINE]Related articlesFree article

    8.

    Screening for type 2 diabetes mellitus: a cost-effectiveness analysis.

    Hoerger TJ, Harris R, Hicks KA, Donahue K, Sorensen S, Engelgau M.

    Ann Intern Med. 2004 May 4;140(9):689-99.PMID: 15126252 [PubMed - indexed for MEDLINE]Related articlesFree article

    9.

    The cost effectiveness of ACE inhibitors as first-line antihypertensive therapy.

    Nordmann AJ, Krahn M, Logan AG, Naglie G, Detsky AS.

    Pharmacoeconomics. 2003;21(8):573-85.PMID: 12751915 [PubMed - indexed for MEDLINE]Related articles

    10.

    An economic analysis of captopril in the treatment of diabetic nephropathy. The Collaborative Study Group.

    Rodby RA, Firth LM, Lewis EJ.

    Diabetes Care. 1996 Oct;19(10):1051-61.PMID: 8886549 [PubMed - indexed for MEDLINE]Related articles

    11.

    Cost-effectiveness of screening and vaccinating Asian and Pacific Islander adults for hepatitis B.

    Hutton DW, Tan D, So SK, Brandeau ML.

    Ann Intern Med. 2007 Oct 2;147(7):460-9.PMID: 17909207 [PubMed - indexed for MEDLINE]Related articlesFree article

    12.

    Pharmacoeconomic analysis of angiotensin-converting enzyme inhibitors in type 2 diabetes: a Markov model.

    Campbell HM, Boardman KD, Dodd MA, Raisch DW.

    Ann Pharmacother. 2007 Jul;41(7):1101-10. Epub 2007 Jul 3.PMID: 17609233 [PubMed - indexed for MEDLINE]Related articles

    13.

    Eliminating out-of-pocket drug costs may improve outcomes after myocardial infarction--but at what cost to Medicare?

    Moran A, Goldman L.

    Nat Clin Pract Cardiovasc Med. 2008 Oct;5(10):606-7. Epub 2008 Aug 12.PMID: 18695697 [PubMed - indexed for MEDLINE]Related articles

    14.

    Medicare coverage of angiotensin-converting enzyme inhibitors.

    Velakaturi VN.

    Ann Intern Med. 2005 Dec 20;143(12):918; author reply 918. No abstract available. PMID: 16365479 [PubMed - indexed for MEDLINE]Related articlesFree article

    15.

    Cost-effectiveness of early irbesartan treatment versus control (standard antihypertensive medications excluding ACE inhibitors, other angiotensin-2 receptor antagonists, and dihydropyridine calcium channel blockers) or late irbesartan treatment in patients with type 2 diabetes, hypertension, and renal disease.

    Palmer AJ, Annemans L, Roze S, Lamotte M, Lapuerta P, Chen R, Gabriel S, Carita P, Rodby RA, de Zeeuw D, Parving HH.

    Diabetes Care. 2004 Aug;27(8):1897-903.PMID: 15277414 [PubMed - indexed for MEDLINE]Related articlesFree article

    16.

    Screening for proteinuria in US adults: a cost-effectiveness analysis.

    Boulware LE, Jaar BG, Tarver-Carr ME, Brancati FL, Powe NR.

    JAMA. 2003 Dec 17;290(23):3101-14.PMID: 14679273 [PubMed - indexed for MEDLINE]Related articlesFree article

    17.

    Clinical outcomes and cost-effectiveness of strategies for managing people at high risk for diabetes.

    Eddy DM, Schlessinger L, Kahn R.

    Ann Intern Med. 2005 Aug 16;143(4):251-64.PMID: 16103469 [PubMed - indexed for MEDLINE]Related articlesFree article

    18.

    The cost-effectiveness of lifestyle modification or metformin in preventing type 2 diabetes in adults with impaired glucose tolerance.

    Herman WH, Hoerger TJ, Brandle M, Hicks K, Sorensen S, Zhang P, Hamman RF, Ackermann RT, Engelgau MM, Ratner RE; Diabetes Prevention Program Research Group.

    Ann Intern Med. 2005 Mar 1;142(5):323-32.PMID: 15738451 [PubMed - indexed for MEDLINE]Related articlesFree article

    19.

    Cost-effectiveness of vaccination against invasive pneumococcal disease among people 50 through 64 years of age: role of comorbid conditions and race.

    Sisk JE, Whang W, Butler JC, Sneller VP, Whitney CG.

    Ann Intern Med. 2003 Jun 17;138(12):960-8.PMID: 12809452 [PubMed - indexed for MEDLINE]Related articlesFree article

    20.

    Should all Pima Indians with type 2 diabetes mellitus be prescribed routine angiotensin-converting enzyme inhibition therapy to prevent renal failure?

    Kiberd BA, Jindal KK.

    Mayo Clin Proc. 1999 Jun;74(6):559-64.PMID: 10377929 [PubMed - indexed for MEDLINE]Related articles

    Supplemental Content

    Filter your results:

    Find related data

    Recent activity